H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on TVTX stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Buy rating due to a combination of factors including Travere Therapeutics’ strong financial performance and strategic milestones. The company reported a significant earnings per share (EPS) of $0.28 for the third quarter of 2025, surpassing both Pantginis’s and market expectations. This positive variance was largely due to a $40 million milestone payment from CSL Vifor, as well as higher-than-anticipated sales of FILSPARI, which generated $90.9 million in revenue.
Additionally, Travere Therapeutics is showing promising developments in its pipeline, with ongoing studies and upcoming data presentations for FILSPARI in IgAN and FSGS. The company is also preparing to restart enrollment for the Phase 3 HARMONY study and has expanded its SPARTAN and SPARX studies. These strategic initiatives, combined with strong cash reserves and the potential for further market expansion, underpin Pantginis’s optimistic outlook and Buy rating for Travere Therapeutics.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $40.00 price target.